A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

NCT01436201 · Completed

Last updated 2026-05-28

This clinical trial tests how the diabetes medication dulaglutide affects the way the body processes digoxin in healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 24 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2011-09 · est. completion 2011-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01436201 ↗

Description as written by the study sponsor.

The purpose of this study is to study how the body processes digoxin and the effect of dulaglutide on how digoxin is processed by the body. Information about any side effects that may occur will also be collected. This study is for research purposes only and is not intended to treat any medical condition. This research study requires that a blood sample be obtained and stored for future research involving genetic analysis.

Treatments tested

Digoxin Drug

Administered orally
Dulaglutide also known as LY2189265 Biologic

Administered as subcutaneous injection

Main thing measured	Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01436201 ↗